



25 **ABSTRACT**

26 **Purpose:** This study aims to use proteomic profiling of sonicate fluid samples to compare host  
27 response during *Staphylococcus aureus*-associated periprosthetic joint infection (PJI) and non-  
28 infected arthroplasty failure (NIAF) and investigate novel biomarkers to increase diagnostic  
29 accuracy.

30 **Experimental Design:** In this pilot study, eight sonicate fluid samples (four from NIAF and four  
31 from *Staphylococcus aureus* PJI) were studied. Samples were reduced, alkylated and  
32 trypsinized overnight, followed by analysis using liquid chromatography-tandem mass  
33 spectrometry (LC-MS/MS) on a high-resolution Orbitrap Eclipse mass spectrometer. MaxQuant  
34 software suite was used for protein identification, filtering, and label-free quantitation.

35 **Results:** Principal component analysis of the identified proteins clearly separated *S. aureus* PJI  
36 and NIAF samples. Overall, 810 proteins were quantified in any three samples from each group  
37 and 35 statistically significant differentially abundant proteins (DAPs) were found (2-sample t-  
38 test p-values  $\leq 0.05$  and  $\log_2$ fold-change values  $\geq 2$  or  $\leq -2$ ). Gene ontology pathway analysis  
39 found that microbial defense responses, specifically those related to neutrophil activation, were  
40 increased in *S. aureus* PJI compared to NIAF samples.

41 **Conclusion and Clinical Relevance:** Proteomic profiling of sonicate fluid using LC-MS/MS,  
42 alone or in combination with complementary protein analyses, differentiated *S. aureus* PJI and  
43 NIAF in this pilot study.

44 **ABBREVIATIONS**

45 **PJI:** periprosthetic joint infection

46 **NIAF:** non-infectious arthroplasty failure

47 **DAPs:** differentially abundant proteins

48 **LC-MS/MS:** liquid chromatography-tandem mass spectrometry

49 **CCL20:** chemokine ligand 20

50 **SARS-CoV-2:** severe acute respiratory syndrome coronavirus 2

51 **LTF:** lactotransferrin

52 **LCN2:** lipocalin-2

53 **MPO:** myeloperoxidase

54 **S100A9:** calprotectin-A9

55 **S100A8:** calprotectin-A8

56 **CTSG:** cathepsin G

57 **ELANE:** neutrophil elastase

58 **RNASE3:** eosinophil cationic protein

59 **ERN1:** endoplasmic reticulum to nucleus signaling 1

60 **MMP9:** matrix metalloproteinase-9

61 **LYZ:** lysozyme C

62 **HP:** haptoglobin

63 **LMNB1:** lamin-B1

64 **PYGL:** glycogen phosphorylase, liver form

65 **LRG1** leucine-rich alpha-2-glycoprotein

66 **CRTAC1:** cartilage acidic protein 1

67 **MCAM:** cell surface glycoprotein MUC18

- 68 **IFI30:** IFI30 lysosomal thiol reductase
- 69 **SPP1:** osteopontin
- 70 **HEXB:** beta-hexosaminidase subunit beta
- 71 **PRG4** proteoglycan 4
- 72 **RNASE1:** ribonuclease pancreatic
- 73 **DCD:** dermcidin
- 74 **CD44:** CD44 antigen
- 75 **ANXA2:** annexin A2
- 76 **SERPINB6:** serpin B6
- 77 **BCAT1:** branched-chain-amino-acid aminotransferase
- 78 **DLST:** dihydrolipoamide S-succinyltransferase
- 79 **HSPB1:** heat shock protein beta-1
- 80 **EEA1:** early endosome antigen 1
- 81 **COL1A2:** collagen alpha-2(I) chain
- 82 **FABP5:** fatty acid-binding protein, epidermal
- 83 **FBP1:** fructose-1,6-bisphosphatase 1
- 84 **FABP3:** fatty acid-binding protein, heart
- 85 **CTSD:** cathepsin D
- 86 **PEA:** proximity extension assay
- 87 **TCEP:** tris(2-carboxyethyl)phosphine
- 88 **FDR:** false discovery rate

89 **STATEMENT OF CLINICAL SIGNIFICANCE**

90 Periprosthetic joint infection (PJI) is a major complication of joint arthroplasty. There is no  
91 perfect assay for differentiating PJI from non-infectious arthroplasty failure (NIAF). Although  
92 some studies have recently employed 'omics technologies, further work is needed to discover  
93 novel and sensitive biomarkers and increase accuracy. A comprehensive proteomic analysis of  
94 sonicate fluid from PJI, a specimen derived from sonication of resected implants to sample  
95 their surfaces, is not yet reported.

## 96 1. INTRODUCTION

97 Periprosthetic joint infection (PJI) is a major cause of arthroplasty failure after total knee or hip  
98 replacement surgery. Of the estimated 7 million Americans living with a total knee or hip  
99 arthroplasty as of 2010, about 1-2% will go on to get a PJI [1-5]. As the number of individuals who  
100 undergo arthroplasty surgery continues to rise, so will the number of PJIs, resulting in extended  
101 hospital stays, increased antimicrobial usage, and an estimated \$1.85 billion in annual  
102 healthcare costs by 2030 [6-9]. *Staphylococcus aureus* is a common cause of PJI, associated  
103 with robust biofilm production, production of numerous virulence factors, and resistance to  
104 antimicrobial agents and the host immune response [1,2,10-15].

105 Some PJI cases can be difficult to differentiate from non-infectious arthroplasty failure  
106 (NIAF) [16-21]. Typically, arthroplasty failure is treated with resection of the failed implant and one-  
107 or two-stage revision surgery or debridement and implant retention, alongside an extended  
108 course of antimicrobial agents [1,22-24]. Microbial- and host-based assays are used to diagnose  
109 PJI. Microbial diagnostics may be limited by negative growth in culture or negative results of  
110 molecular diagnostics, or conversely, falsely-positive results as a result of detection of  
111 contaminants [25]. Additional host-derived biomarkers for PJI, such as erythrocyte sedimentation  
112 rate in blood; nucleated cell count and neutrophil percentage in synovial fluid; and intraoperative  
113 tissue histology and purulence, can provide evidence of underlying infection [1,22,26]. Host  
114 proteomic profiling has also been shown to have the potential to differentiate PJI from NIAF, with  
115 increased expression of c-reactive protein, D-dimer, chemokine ligand 20 (CCL20), calprotectin,  
116 lipocalin, lactotransferrin, and many others, in PJI compared to NIAF patient samples [26-35].  
117 Measurement of one protein, alpha-defensin, in synovial fluid has been approved by the United  
118 States Food and Drug Administration as an aid for the detection of PJI [33,36].

119 Multi-omics approaches have recently been investigated as potential alternatives to  
120 overcome limitations of currently used diagnostic tools [26,29,37-40]. Previous studies have shown  
121 that liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based profiling may be able  
122 to differentiate synovial fluid samples from PJI and NIAF patients [31,41]. Analysis of sonicate fluid,  
123 a sample-type that directly interrogates the site of infection - the implant surface -, may  
124 hypothetically allow for enhanced differentiation of infected and non-infected individuals and  
125 potentially PJI biomarker discovery [37,40,42-44]. Mass spectrometry-based proteomic analysis  
126 provides an unbiased and in-depth overview of the protein expression alterations in biological  
127 samples. Our group has previously employed mass spectrometry-based proteomics in  
128 developing assays of potential diagnostic utility [45,46] and in studying host response to severe  
129 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection [47,48]. This pilot study  
130 was aimed to evaluate the feasibility of proteomic analysis of sonicate fluid to reflect the host  
131 response to PJI. The advancement of proteomics-based profiling of patient samples during PJI  
132 could yield novel insights into underlying biological interactions.

## 133 **2. MATERIAL AND METHODS**

### 134 **2.1 Sonicate fluid harvest and cohort**

135 Sonicate fluid samples were collected between October 2013 and July 2017 from patients  
136 undergoing revision total hip or knee arthroplasty; arthroplasty components were removed and  
137 subjected to sonication for clinical purposes, as previously described; their use in this study was  
138 approved by the Mayo Clinic Institutional Review Board (09-000808) (23). Four NIAF and four  
139 *S. aureus* PJI sonicate fluid samples were analyzed. Infection status was determined by the  
140 2018 Musculoskeletal Infection Society and International Consensus Meeting criteria [49].

### 141 **2.2 Protein extraction and LC-MS/MS analysis**

142 100 µl of sonicate fluid samples were adjusted to 0.2% Rapigest followed by heating at 90 °C  
143 for 5 minutes. Samples were then reduced with 5 mM tris(2-carboxyethyl)phosphine (TCEP) for  
144 45 minutes at room temperature and alkylated with 20 mM Iodoacetamide for 25 minutes in the  
145 dark. Trypsin enzyme was added in the ratio of 1:20 for overnight digestion at 37 °C. Following  
146 C<sub>18</sub> cleanup, 2 µg of peptides were subjected to quantitative LC-MS/MS analysis on a high-  
147 resolution Orbitrap Eclipse Tribrid mass spectrometer connected to UltiMate 3000 RSLC nano  
148 system (Thermo Scientific, Waltham, MA). Separation of peptides includes initial trapping on a  
149 trap column (PepMap C18, 2 cm × 100 µm, 100 Å, Thermo Scientific, San Jose, CA) using 0.1%  
150 formic acid (solvent A) followed by gradient elution (3% to 28% to 40%) using acetonitrile, 0.1%  
151 formic acid (solvent B) on an analytical column (EasySpray 50 cm × 75 µm, C18 1.9 µm, 100 Å,  
152 Thermo Scientific, San Jose, CA). Each run was started with equilibration of both columns for 5  
153 minutes and the overall time for each run was 240 minutes. As the peptides were eluting, the  
154 Orbitrap was operated in a data dependent mode with a cycle time of 2 seconds. Initially, the  
155 precursor MS scan was recorded for 350-1500 m/z using a normalized AGC target of 100%,



156 injection time of 50 ms and 60,000 resolution. Precursors with a minimum intensity threshold of  
157 20,000 and charge states 2-7 were taken for MS/MS starting from high intensity precursors.  
158 Monoisotopic precursor selection was also enabled. Quadrupole was used for precursor  
159 isolation with 1.6 m/z isolation width and fragmented with normalized HCD energy of 28% and  
160 resulting fragment ions was recorded in Orbitrap analyzer. Fragment ion spectrum was recorded  
161 at 15,000 resolution using normalized AGC target of 200% and maximum injection time of 120  
162 ms. Dynamic exclusion of 30 seconds was used to prevent repeated fragmentation of the  
163 precursor ions.

### 164 **2.3 LC-MS/MS raw data analysis**

165 MaxQuant software suite (V 2.0.1.0) was used for protein identification and quantitation.  
166 Database searching was performed against human UniProt protein database with *in silico* trypsin  
167 digestion set to be specific and maximum of 2 missed cleavages allowed. Default mass tolerance  
168 settings of 20 pm for first search and 4.5 ppm for main search were used. Oxidation (Methionine)  
169 and protein N-terminal acetylation were used as dynamic modifications, whereas  
170 carbamidomethylation (cysteine) was used as static modification. Proteins were filtered at 1%  
171 protein-level false discovery rate (FDR). LFQ algorithm within MaxQuant was used for label-free  
172 quantitation and match between the runs option was enabled with match time window of 1 minute  
173 to reduce missing values. Finally, label-free quantified values were logarithmized and proteins  
174 not quantified in at least three samples in each group were eliminated.

### 175 **2.4 Data organization and statistical analysis**

176 Quantitative data were organized and graphed in RStudio v1.2.5042 <sup>[50]</sup> using the R-packages  
177 “ComplexHeatmap” <sup>[51]</sup> for heatmap creation and “Factoextra” <sup>[52]</sup> for principal component  
178 analysis. Protein-specific analyses were conducted, and a volcano plot created in Graphpad

179 Prism 9 v9.2.0 (San Diego, CA). Enrichr was used for gene ontology pathway analysis [53-55].  
180 Statistical significance was determined using 2-sample t-test with multiple hypothesis correction  
181 ( $p$ -values  $\leq 0.05$  and  $\log_2$ fold-change values  $\geq 2$  or  $\leq -2$ ).

### 182 **3. RESULTS AND DISCUSSION**

#### 183 **3.1 Cohort differential protein abundance characterization**

184 In this study, quantitative LC-MS/MS analysis was used to characterize the host proteomic  
185 profile of four NIAF and four *S. aureus* PJI sonicate fluid samples and determine whether NIAF  
186 and *S. aureus* PJI-associated samples can be differentiated. Eight hundred and ten proteins  
187 were quantified in at least three of four samples each of *S. aureus* PJI and NIAF cases, of which  
188 35 differentially abundant proteins (DAPs) were identified (Table 1, Figure 1). Fifteen DAPs were  
189 increased in *S. aureus* PJI compared to NIAF samples, including lactotransferrin (LTF) [ $\log_2$ fold-  
190 change = 5.2], lipocalin-2 (LCN2) [ $\log_2$ fold-change = 5.0], myeloperoxidase (MPO) [ $\log_2$ fold-  
191 change = 4.9], calprotectin-A9 (S100A9 subunit) [ $\log_2$ fold-change = 4.5], calprotectin-A8  
192 (S100A8 subunit) [ $\log_2$ fold-change = 4.0], cathepsin G (CTSG) [ $\log_2$ fold-change = 4.0],  
193 neutrophil elastase (ELANE) [ $\log_2$ fold-change = 3.8], eosinophil cationic protein (RNASE3)  
194 [ $\log_2$ fold-change = 3.6], endoplasmic reticulum to nucleus signaling 1 (ERN1) [ $\log_2$ fold-change  
195 = 3.2], matrix metalloproteinase-9 (MMP9) [ $\log_2$ fold-change = 2.9], lysozyme C (LYZ) [ $\log_2$ fold-  
196 change = 2.7], haptoglobin (HP) [ $\log_2$ fold-change = 2.6], lamin-B1 (LMNB1) [ $\log_2$ fold-change =  
197 2.5], glycogen phosphorylase, liver form (PYGL) [ $\log_2$ fold-change = 2.5], leucine-rich alpha-2-  
198 glycoprotein (LRG1) [ $\log_2$ fold-change = 2.2] (Table 1).

199 Twenty of the 35 DAPs were decreased in *S. aureus* PJI compared to NIAF sonicate fluid  
200 samples (Table 1, Figure 1), including cartilage acidic protein 1 (CRTAC1) [ $\log_2$ fold-change = -  
201 5.3], cell surface glycoprotein MUC18 (MCAM) [ $\log_2$ fold-change = -4.2], IFI30 lysosomal thiol

202 reductase (IFI30) [ $\log_2$ fold-change = -2.8], osteopontin (SPP1) [ $\log_2$ fold-change = -2.7], beta-  
203 hexosaminidase subunit beta (HEXB) [ $\log_2$ fold-change = -2.6], proteoglycan 4 (PRG4) [ $\log_2$ fold-  
204 change = -2.6], ribonuclease pancreatic (RNASE1) [ $\log_2$ fold-change = -2.5], dermcidin (DCD)  
205 [ $\log_2$ fold-change = -2.5], CD44 antigen (CD44) [ $\log_2$ fold-change = -2.5], annexin A2 (ANXA2)  
206 [ $\log_2$ fold-change = -2.4], serpin B6 (SERPINB6) [ $\log_2$ fold-change = -2.4], branched-chain-amino-  
207 acid aminotransferase (BCAT1) [ $\log_2$ fold-change = -2.3], dihydrolipoamide S-  
208 succinyltransferase (DLST) [ $\log_2$ fold-change = -2.3], heat shock protein beta-1 (HSPB1)  
209 [ $\log_2$ fold-change = -2.1], early endosome antigen 1 (EEA1) [ $\log_2$ fold-change = -2.1], collagen  
210 alpha-2(I) chain (COL1A2) [ $\log_2$ fold-change = -2.1], fatty acid-binding protein, epidermal  
211 (FABP5) [ $\log_2$ fold-change = -2.1], fructose-1,6-bisphosphatase 1 (FBP1) [ $\log_2$ fold-change = -  
212 2.0], fatty acid-binding protein, heart (FABP3) [ $\log_2$ fold-change = -2.0], cathepsin D (CTSD)  
213 [ $\log_2$ fold-change = -2.0].

214 Unsupervised clustering analysis of the DAPs showed distinct pattern of expression  
215 between *S. aureus* PJI and NIAF sonicate fluid samples. (Figure 2A). Differential clustering was  
216 also observed via principal component analysis, where *S. aureus* PJI and NIAF sonicate fluid  
217 samples were separated along dimension 1, accounting for 81.8% of the total variation of the  
218 dataset (Figure 2B).

### 219 **3.2 Gene ontology analyses of differentially abundant proteins**

220 To better understand the functional outcome of sonicate fluid DAPs in PJI *versus* NIAF,  
221 gene ontology analysis was conducted [53-55]. Unsurprisingly, biological processes related to  
222 neutrophil antimicrobial activity, such as activation and degranulation, were increased in *S.*  
223 *aureus* PJI compared to NIAF sonicate fluid samples. Overall antimicrobial responses against  
224 bacteria and fungi were also increased in *S. aureus* PJI (Figure 3A). Next, molecular functions

225 enriched among DAPs were examined. Inflammatory pathways, such as those related to  
226 peptidase activity and RAGE receptor binding were increased in *S. aureus* PJI samples. Metal  
227 ion-binding pathways were also increased in *S. aureus* PJI samples. In fact, many of the DAPs  
228 most increased in *S. aureus* PJI, such as LTF, LCN2, and S100A8/A9, are known metal ion  
229 sequestration proteins reported to be important for the antimicrobial nutritional immunity  
230 response in other infection types [56-58]. Though increases of metal ion binding proteins have  
231 recently been shown to be clinical biomarkers of PJI biomarkers [27,28,30,31,59,60], the functional  
232 role of nutritional immunity during PJI is an area needing further investigation.

### 233 **3.3 Further validation of differentially abundant proteins**

234 While the mass-spectrometry-based proteomic profiling described here identified DAPs and  
235 differentiated *S. aureus* and NIAF sonicate fluid samples, the sample size was low, and further  
236 validation was necessary. To do so, results were compared to previous transcriptomic and  
237 proteomic analyses of sonicate fluid samples conducted by our group. Transcriptomic analysis  
238 of eight *S. aureus* PJI and forty NIAF sonicate fluid samples, including the eight that underwent  
239 LC-MS/MS here, has been recently reported [40]. Of the thirty-five DAPs found via LC-MS/MS,  
240 18 had differentially expressed transcripts via RNA-sequencing. In all but one recapitulated case,  
241 whether the target was up- or downregulated in *S. aureus* PJI compared to NIAF remained  
242 consistent. MMP9 was found to have increased protein abundance but decreased transcriptomic  
243 abundance in *S. aureus* PJI compared to NIAF samples.

244 Proteomic profiling of 200 sonicate fluid samples, including the eight that underwent LC-  
245 MS/MS, was recently reported using the proximity extension assay (PEA) platform from Olink  
246 Proteomics (Uppsala, Sweden) [34,61]. PEA showed that, of the 92 proteins included in the Olink  
247 Inflammation Panel, 37 DAPs were found when comparing PJI and NIAF samples [34].

248 Interestingly, there was no overlap across the 37 DAPs identified through PEA platform to the  
249 35 DAPs identified by LC-MS/MS analysis. This lack of overlap is explained by specific  
250 characteristics of each platform. PEA is a targeted method that uses antibodies conjugated to  
251 oligonucleotides and PCR amplification to process and quantify proteins, allowing for  
252 assessment of low-concentration proteins. However, this analysis is limited to detection to the  
253 specific protein targets included in the panel <sup>[61]</sup>. In contrast, LC-MS/MS is an unbiased approach,  
254 which can quantify proteins in a global fashion that are above the detection limit <sup>[62]</sup>. Thus, a  
255 targeted approach like PEA is complementary to an LC-MS/MS approach. Thus, combining LC-  
256 MS/MS with PEA provides a holistic proteomic profile for protein biomarker discovery.

257         Lastly, results were compared to those found by Li et al. which analyzed 51 PJI and 66  
258 non-PJI synovial fluid samples identified by LC-MS/MS <sup>[41]</sup>. Of the 35 DAPs found in sonicate  
259 fluid, 15, including LTF, MPO, S100A9, CTSG, S100A8, ELANE, MMP9, HP, PYGL, CTSD,  
260 FABP5, BCAT1, PRG4, HEXB, and CRTAC1, were also found in synovial fluid. Proteomic  
261 analysis of synovial fluid revealed 281 DAPs, a higher number than identified herein in sonicate  
262 fluid, with the caveat that more patients and bacterial species causing PJI were analyzed in the  
263 synovial fluid study. That proteomic analyses of sonicate and synovial fluid were not fully  
264 concordant affirms the potential value of interrogating both sample types, though ideally synovial  
265 and sonicate fluids from the same patients, collected at the same time and analyzed using the  
266 same methods, should be analyzed.

#### 267 **4. CONCLUDING REMARKS**

268 Overall, results from this study indicate that proteomic profiling of sonicate fluid using mass  
269 spectrometry-based proteomic analysis differentiates *S. aureus* PJI and NIAF samples. This

- 270 study supports the concept of conducting larger and more thorough future proteomic profiling
- 271 studies using combinational analyses and complementary sample-types.

272 **ACKNOWLEDGEMENTS**

273 This research was supported by the National Institute of Arthritis and Musculoskeletal and Skin  
274 Diseases of the National Institutes of Health under Award Number NIH R01 AR056647. CF  
275 was supported by the Mayo Clinic Graduate School of Biomedical Sciences and the Ph.D.  
276 Training Grant in Basic Immunology (NIAID T32 AI07425-25). The content is solely the  
277 responsibility of the authors and does not necessarily represent the official views of the NIH.  
278 We would like to acknowledge Suzannah Schmidt-Malan, M.S., Melissa Karau, M.S., and the  
279 rest of the Mayo Clinic Infectious Diseases Research Laboratory for accessioning and  
280 maintaining the sonicate fluid biobank.

281 **PATIENT CONSENT STATEMENT**

282 The study was approved by the Mayo Clinic Institutional Review Board (#09-000808).

283 **AUTHORS' CONTRIBUTIONS**

284 CF's roles were conceptualization, data curation, formal analysis, investigation, visualization,  
285 writing – original draft, and writing – review & editing. KM's roles were mass spectrometry  
286 analysis, data analysis and visualization, and writing – review & editing. KG's roles were project  
287 administration, supervision, and writing – review & editing. MA's roles were resource provision  
288 and writing – review & editing. AP's roles were resource provision, supervision, and writing –  
289 review & editing. RP's roles were conceptualization, funding acquisition, project administration,  
290 resource provision, supervision, and writing – review & editing. All authors read and approved  
291 the final manuscript.

292 **CONFLICT OF INTEREST**

293 RP reports grants from ContraFect, TenNor Therapeutics Limited, and BioFire. RP is a  
294 consultant to PhAST, Torus Biosystems, Day Zero Diagnostics, Mammoth Biosciences, and  
295 HealthTrackRx; monies are paid to Mayo Clinic. Mayo Clinic and RP have a relationship with  
296 Pathogenomix. RP has research supported by Adaptive Phage Therapeutics. Mayo Clinic has  
297 a royalty-bearing know-how agreement and equity in Adaptive Phage Therapeutics. RP is also  
298 a consultant to Netflix, Abbott Laboratories, and CARB-X. In addition, RP has a patent on  
299 *Bordetella pertussis/parapertussis* PCR issued, a patent on a device/method for sonication  
300 with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance  
301 issued. RP receives honoraria from the NBME, Up-to-Date and the Infectious Diseases Board  
302 Review Course. MPA receives royalties from Stryker on certain hip and knee products and  
303 serve on the AAOS Board of Directors. All other authors report no conflicts of interest.

304 **DATA AVAILABILITY STATEMENT**

305 The mass spectrometry proteomics data have been deposited to the Proteome Xchange  
306 Consortium via the PRIDE partner repository with the dataset identifier PXD038928.



307 **REFERENCES**

- 308 [1] Tande, A. J., & Patel, R. (2014). Prosthetic joint infection. *Clin Microbiol Rev*, 27(2), 302-345.  
309 doi: 10.1128/CMR.00111-13
- 310 [2] Zimmerli, W. (2006). Infection and musculoskeletal conditions: Prosthetic-joint-associated  
311 infections. *Best Pract Res Clin Rheumatol*, 20(6), 1045-1063. doi:  
312 10.1016/j.berh.2006.08.003
- 313 [3] Trampuz, A., & Widmer, A. F. (2006). Infections associated with orthopedic implants. *Curr  
314 Opin Infect Dis*, 19(4), 349-356. doi: 10.1097/01.qco.0000235161.85925.e8
- 315 [4] Shuman, E. K., A. U., & Malani, P. N. (2012). Management and prevention of prosthetic joint  
316 infection. *Infect Dis Clin North Am*, 26(1):29-39. doi: 10.1016/j.idc.2011.09.011.
- 317 [5] Maradit Kremers, H., Larson, D. R., Crowson, C. S., Kremers, W. K., Washington, R. E.,  
318 Steiner, C. A., . . . Berry, D. J. (2015). Prevalence of total hip and knee replacement in  
319 the United States. *The Journal of bone and joint surgery. American volume*, 97(17), 1386-  
320 1397. doi: 10.2106/JBJS.N.01141
- 321 [6] Kurtz, S., Ong, K., Lau, E., Mowat, F., & Halpern, M. (2007). Projections of primary and  
322 revision hip and knee arthroplasty in the United States from 2005 to 2030. *The Journal of  
323 bone and joint surgery. American volume*, 89(4), 780-785. doi: 10.2106/JBJS.F.00222
- 324 [7] Gutowski, C. J., Chen, A. F., & Parvizi, J. (2016). The incidence and socioeconomic impact  
325 of periprosthetic joint infection: United States perspective *Periprosthetic Joint Infections*  
326 (pp. 19-26): Springer.
- 327 [8] Jason Akindolire, M., Morcos, M. W., Howard, J. L., Lanting, B. A., & Vasarhelyi, E. M. (2020).  
328 The economic impact of periprosthetic infection in total hip arthroplasty. *Can J Surg*,  
329 63(1), E52-E56.
- 330 [9] Premkumar, A., Kolin, D. A., Farley, K. X., Wilson, J. M., McLawhorn, A. S., Cross, M. B., &  
331 Sculco, P. K. (2021). Projected economic burden of periprosthetic joint infection of the hip  
332 and knee in the United States. *J Arthroplasty*, 36(5), 1484-1489 e1483. doi:  
333 10.1016/j.arth.2020.12.005
- 334 [10] Benito, N., Franco, M., Ribera, A., Soriano, A., Rodriguez-Pardo, D., Sorlí, L., . . . Puente,  
335 A. (2016). Time trends in the aetiology of prosthetic joint infections: a multicentre cohort  
336 study. *Clin Microbiol Infect*, 22(8), 732.e731-732.e738. doi:  
337 <https://doi.org/10.1016/j.cmi.2016.05.004>
- 338 [11] Hsieh, P.-H., Lee, M. S., Hsu, K.-Y., Chang, Y.-H., Shih, H.-N., & Ueng, S. W. (2009). Gram-  
339 negative prosthetic joint infections: Risk factors and outcome of treatment. *Clin Infect Dis*,  
340 49(7), 1036-1043. doi: 10.1086/605593
- 341 [12] Corvec, S., Portillo, M. E., Pasticci, B. M., Borens, O., & Trampuz, A. (2012). Epidemiology  
342 and new developments in the diagnosis of prosthetic joint infection. *Int J Artif Organs*,  
343 35(10), 923-934. doi: 10.5301/ijao.5000168
- 344 [13] Schilcher, K., & Horswill, A. R. (2020). Staphylococcal biofilm development: Structure,  
345 regulation, and treatment strategies. *Microbiol Mol Biol Rev*, 84(3), e00026-00019. doi:  
346 10.1128/MMBR.00026-19
- 347 [14] Arciola, C. R., Campoccia, D., & Montanaro, L. (2018). Implant infections: Adhesion, biofilm  
348 formation and immune evasion. *Nat Rev Microbiol*, 16(7), 397-409. doi: 10.1038/s41579-  
349 018-0019-y
- 350 [15] Stevoska, S., Himmelbauer, F., Stifftinger, J., Stadler, C., Pisecky, L., Gotterbarm, T., &  
351 Klasan, A. (2022). Significant difference in antimicrobial resistance of bacteria in septic

- 352 revision between total knee arthroplasty and total hip arthroplasty. *Antibiotics*, 11(2), 249.  
353 doi: 10.3390/antibiotics11020249
- 354 [16] Bonnin, M., Deschamps, G., Neyret, P., & Chambat, P. (2000). [Revision in non-infected  
355 total knee arthroplasty: An analysis of 69 consecutive cases]. *Revue de chirurgie*  
356 *orthopedique et reparatrice de l'appareil moteur*, 86(7), 694-706.
- 357 [17] Kelmer, G., Stone, A. H., Turcotte, J., & King, P. J. (2021). Reasons for revision: Primary  
358 total hip arthroplasty mechanisms of failure. *J Am Acad Orthop Surg*, 29(2), 78-87. doi:  
359 10.5435/JAAOS-D-19-00860
- 360 [18] Mathis, D. T., Lohrer, L., Amsler, F., & Hirschmann, M. T. (2021). Reasons for failure in  
361 primary total knee arthroplasty - An analysis of prospectively collected registry data. *J*  
362 *Orthop*, 23, 60-66. doi: 10.1016/j.jor.2020.12.008
- 363 [19] Athanasou, N. A. (2016). The pathobiology and pathology of aseptic implant failure. *Bone*  
364 *Joint Res*, 5(5), 162-168. doi: 10.1302/2046-3758.55.BJR-2016-0086
- 365 [20] Kenney, C., Dick, S., Lea, J., Liu, J., & Ebraheim, N. A. (2019). A systematic review of the  
366 causes of failure of revision total hip arthroplasty. *J Orthop*, 16(5), 393-395. doi:  
367 10.1016/j.jor.2019.04.011
- 368 [21] Gazendam, A., Wood, T. J., Tushinski, D., & Bali, K. (2022). Diagnosing periprosthetic joint  
369 infection: A scoping review. *Curr Rev Musculoskelet Med*, 15(3), 219-229. doi:  
370 10.1007/s12178-022-09751-w
- 371 [22] Osmon, D. R., Berbari, E. F., Berendt, A. R., Lew, D., Zimmerli, W., Steckelberg, J. M., . . .  
372 America, I. D. S. o. (2013). Diagnosis and management of prosthetic joint infection:  
373 clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis*,  
374 56(1), e1-e25. doi: 10.1093/cid/cis803
- 375 [23] Kuzyk, P. R., Dhotar, H. S., Sternheim, A., Gross, A. E., Safir, O., & Backstein, D. (2014).  
376 Two-stage revision arthroplasty for management of chronic periprosthetic hip and knee  
377 infection: techniques, controversies, and outcomes. *J Am Acad Orthop Surg*, 22(3), 153-  
378 164. doi: 10.5435/JAAOS-22-03-153
- 379 [24] Li, C., Renz, N., & Trampuz, A. (2018). Management of periprosthetic joint infection. *Hip*  
380 *Pelvis*, 30(3), 138-146. doi: 10.5371/hp.2018.30.3.138
- 381 [25] Parvizi, J., Ghanem, E., Menashe, S., Barrack, R. L., & Bauer, T. W. (2006). Periprosthetic  
382 infection: what are the diagnostic challenges? *The Journal of bone and joint surgery.*  
383 *American volume*, 88 Suppl 4(suppl\_4), 138-147. doi: 10.2106/JBJS.F.00609
- 384 [26] Keemu, H., Vaura, F., Maksimow, A., Maksimow, M., Jokela, A., Hollmén, M., & Mäkelä, K.  
385 (2021). Novel biomarkers for diagnosing periprosthetic joint infection from synovial fluid  
386 and serum. *JBJS Open Access*, 6(2).
- 387 [27] Hantouly, A. T., Salameh, M., Toubasi, A. A., Salman, L. A., Alzobi, O., Ahmed, A. F., . . .  
388 Ahmed, G. (2022). Synovial fluid calprotectin in diagnosing periprosthetic joint infection:  
389 A meta-analysis. *Int Ortho*, 46(5), 971-981. doi: 10.1007/s00264-022-05357-6
- 390 [28] Wouthuyzen-Bakker, M., Ploegmakers, J. J. W., Ottink, K., Kampinga, G. A., Wagenmakers-  
391 Huizenga, L., Jutte, P. C., & Kobold, A. C. M. (2018). Synovial calprotectin: An  
392 inexpensive biomarker to exclude a chronic prosthetic joint infection. *J Arthroplasty*, 33(4),  
393 1149-1153. doi: <https://doi.org/10.1016/j.arth.2017.11.006>
- 394 [29] Sharma, K., Ivy, M., Block, D. R., Abdel, M. P., Hanssen, A. D., Beauchamp, C., . . . Patel,  
395 R. (2020). Comparative analysis of 23 synovial fluid biomarkers for hip and knee  
396 periprosthetic joint infection detection. *J Orthop Res*, 38(12), 2664-2674. doi:  
397 10.1002/jor.24766

- 398 [30] Vergara, A., Fernandez-Pittol, M. J., Munoz-Mahamud, E., Morata, L., Bosch, J., Vila, J., . . .  
399 . Casals-Pascual, C. (2019). Evaluation of lipocalin-2 as a biomarker of periprosthetic joint  
400 infection. *J Arthroplasty*, *34*(1), 123-125. doi: 10.1016/j.arth.2018.09.047
- 401 [31] Wang, C., Wang, Q., Li, R., Qin, J., Song, L., Zhang, Q., . . . Wang, C. (2019). LTF, PRTN3,  
402 and MNDA in synovial fluid as promising biomarkers for periprosthetic joint infection:  
403 Identification by quadrupole orbital-trap mass spectrometry. *J Bone Joint Surg*, *101*(24).
- 404 [32] Shahi, A., & Parvizi, J. (2017). The role of biomarkers in the diagnosis of periprosthetic joint  
405 infection. *EFORT open reviews*, *1*(7), 275-278. doi: 10.1302/2058-5241.1.160019
- 406 [33] Pupaibool, J., Fulnecky, E. J., Swords, R. L., Jr., Sistrunk, W. W., & Haddow, A. D. (2016).  
407 Alpha-defensin-novel synovial fluid biomarker for the diagnosis of periprosthetic joint  
408 infection. *Int Orthop*, *40*(12), 2447-2452. doi: 10.1007/s00264-016-3306-0
- 409 [34] Fisher, C. R., Salmons, H. I., Mandrekar, J., Greenwood-Quaintance, K. E., Abdel, M. P., &  
410 Patel, R. (2022). A 92 protein inflammation panel performed on sonicate fluid  
411 differentiates periprosthetic joint infection from non-infectious causes of arthroplasty  
412 failure *in revision*.
- 413 [35] Huang, Z., Zhang, Z., Li, M., Li, W., Fang, X., & Zhang, W. (2022). Synovial fluid neutrophil  
414 gelatinase-associated lipocalin can be used to accurately diagnose prosthetic joint  
415 infection. *Int J Infect Dis*, *123*, 170-175. doi: 10.1016/j.ijid.2022.08.009
- 416 [36] Deirmengian, C., Madigan, J., Kallur Mallikarjuna, S., Conway, J., Higuera, C., & Patel, R.  
417 (2021). Validation of the alpha defensin lateral flow test for periprosthetic joint infection.  
418 *The Journal of bone and joint surgery. American volume*, *103*(2), 115-122. doi:  
419 10.2106/JBJS.20.00749
- 420 [37] Gomez, E., Cazanave, C., Cunningham, S. A., Greenwood-Quaintance, K. E., Steckelberg,  
421 J. M., Uhl, J. R., . . . Patel, R. (2012). Prosthetic joint infection diagnosis using broad-  
422 range PCR of biofilms dislodged from knee and hip arthroplasty surfaces using  
423 sonication. *J Clin Microbiol*, *50*(11), 3501-3508. doi: 10.1128/JCM.00834-12
- 424 [38] Thoendel, M. J., Jeraldo, P. R., Greenwood-Quaintance, K. E., Yao, J. Z., Chia, N.,  
425 Hanssen, A. D., . . . Patel, R. (2018). Identification of prosthetic joint infection pathogens  
426 using a shotgun metagenomics approach. *Clin Infect Dis*, *67*(9), 1333-1338. doi:  
427 10.1093/cid/ciy303
- 428 [39] Korn, M. F., Stein, R. R., Dolf, A., Shakeri, F., Bunes, A., Hilgers, C., . . . Schildberg, F. A.  
429 (2020). High-dimensional analysis of immune cell composition predicts periprosthetic joint  
430 infections and dissects its pathophysiology. *Biomedicines*, *8*(9), 358. doi:  
431 10.3390/biomedicines8090358
- 432 [40] Masters, T. L., Bhagwate, A. V., Dehankar, M. K., Greenwood-Quaintance, K. E., Abdel, M.  
433 P., Mandrekar, J. N., & Patel, R. (2022). Human transcriptomic response to periprosthetic  
434 joint infection. *Gene*, *825*, 146400. doi: 10.1016/j.gene.2022.146400
- 435 [41] Li, R., Song, L., Quan, Q., Liu, M.-W., Chai, W., Lu, Q., . . . Chen, J.-Y. (2021). Detecting  
436 periprosthetic joint infection by using mass spectrometry. *J Bone Joint Surg*, *103*(20).
- 437 [42] Trampuz, A., Piper, K. E., Jacobson, M. J., Hanssen, A. D., Unni, K. K., Osmon, D. R., . . .  
438 Patel, R. (2007). Sonication of removed hip and knee prostheses for diagnosis of  
439 infection. *N Engl J Med*, *357*(7), 654-663. doi: 10.1056/NEJMoa061588
- 440 [43] Piper, K. E., Jacobson, M. J., Cofield, R. H., Sperling, J. W., Sanchez-Sotelo, J., Osmon, D.  
441 R., . . . Patel, R. (2009). Microbiologic diagnosis of prosthetic shoulder infection by use of  
442 implant sonication. *J Clin Microbiol*, *47*(6), 1878-1884. doi: 10.1128/JCM.01686-08

- 443 [44] Kobayashi, H., Oethinger, M., Tuohy, M. J., Procop, G. W., & Bauer, T. W. (2009). Improved  
444 detection of biofilm-formative bacteria by vortexing and sonication: A pilot study. *Clin*  
445 *Orthop Relat Res*, 467(5), 1360-1364. doi: 10.1007/s11999-008-0609-5
- 446 [45] Mangalaparthy, K. K., Chavan, S., Madugundu, A. K., Renuse, S., Vanderboom, P. M.,  
447 Maus, A. D., . . . Pandey, A. (2021). A SISCAPA-based approach for detection of SARS-  
448 CoV-2 viral antigens from clinical samples. *Clin Proteomics*, 18(1), 25. doi:  
449 10.1186/s12014-021-09331-z
- 450 [46] Renuse, S., Vanderboom, P. M., Maus, A. D., Kemp, J. V., Gurtner, K. M., Madugundu, A.  
451 K., . . . Pandey, A. (2021). A mass spectrometry-based targeted assay for detection of  
452 SARS-CoV-2 antigen from clinical specimens. *eBioMedicine*, 69, 103465. doi:  
453 <https://doi.org/10.1016/j.ebiom.2021.103465>
- 454 [47] Vanderboom, P. M., Mun, D.-G., Madugundu, A. K., Mangalaparthy, K. K., Saraswat, M.,  
455 Garapati, K., . . . Pandey, A. (2021). Proteomic signature of host response to SARS-CoV-  
456 2 infection in the nasopharynx. *Mol Cell Proteomics*, 20. doi:  
457 10.1016/j.mcpro.2021.100134
- 458 [48] Chavan, S., Mangalaparthy, K. K., Singh, S., Renuse, S., Vanderboom, P. M., Madugundu,  
459 A. K., . . . Pandey, A. (2021). Mass spectrometric analysis of urine from COVID-19  
460 patients for detection of SARS-CoV-2 viral antigen and to study host response. *J*  
461 *Proteome Res*, 20(7), 3404-3413. doi: 10.1021/acs.jproteome.1c00391
- 462 [49] Parvizi, J., Tan, T. L., Goswami, K., Higuera, C., Della Valle, C., Chen, A. F., & Shohat, N.  
463 (2018). The 2018 definition of periprosthetic hip and knee infection: An evidence-based  
464 and validated criteria. *J Arthroplasty*, 33(5), 1309-1314 e1302. doi:  
465 10.1016/j.arth.2018.02.078
- 466 [50] Team", R. C. (2020). R: A language and environment for statistical computing: R Foundation  
467 for Statistical Computing, Vienna, Austria. Retrieved from <https://www.R-project.org/>
- 468 [51] Gu Z, E. R., Schlesner M. (2016). Complex heatmaps reveal patterns and correlations in  
469 multidimensional genomic data. Retrieved from  
470 <https://www.bioconductor.org/packages/release/bioc/html/ComplexHeatmap.html>
- 471 [52] Kassambara, A., & Mundt, F. (2020). factoextra: Extract and visualize the results of  
472 multivariate data analyses (Version R package version 1.0.7). Retrieved from  
473 <https://CRAN.R-project.org/package=factoextra>
- 474 [53] Chen, E. Y., Tan, C. M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G. V., . . . Ma'ayan, A.  
475 (2013). Enrichr: Interactive and collaborative HTML5 gene list enrichment analysis tool.  
476 *BMC Bioinform*, 14(1), 128. doi: 10.1186/1471-2105-14-128
- 477 [54] Kuleshov, M. V., Jones, M. R., Rouillard, A. D., Fernandez, N. F., Duan, Q., Wang, Z., . . .  
478 Ma'ayan, A. (2016). Enrichr: A comprehensive gene set enrichment analysis web server  
479 2016 update. *Nucleic Acids Res*, 44(W1), W90-W97. doi: 10.1093/nar/gkw377
- 480 [55] Xie, Z., Bailey, A., Kuleshov, M. V., Clarke, D. J. B., Evangelista, J. E., Jenkins, S. L., . . .  
481 Ma'ayan, A. (2021). Gene set knowledge discovery with Enrichr. *Curr Protoc*, 1(3), e90.  
482 doi: <https://doi.org/10.1002/cpz1.90>
- 483 [56] Hood, M. I., & Skaar, E. P. (2012). Nutritional immunity: Transition metals at the pathogen-  
484 host interface. *Nat Rev Microbiol*, 10(8), 525-537. doi: 10.1038/nrmicro2836
- 485 [57] Zackular, J. P., Chazin, W. J., & Skaar, E. P. (2015). Nutritional immunity: S100 proteins at  
486 the host-pathogen interface. *J Biol Chem*, 290(31), 18991-18998. doi:  
487 <https://doi.org/10.1074/jbc.R115.645085>
- 488 [58] Núñez, G., Sakamoto, K., & Soares, M. P. (2018). Innate nutritional immunity. *J Immunol*,  
489 201(1), 11. doi: 10.4049/jimmunol.1800325




- 490 [59] Salari, P., Grassi, M., Cinti, B., Onori, N., & Gigante, A. (2020). Synovial fluid calprotectin  
491 for the preoperative diagnosis of chronic periprosthetic joint infection. *J Arthroplasty*,  
492 35(2), 534-537. doi: 10.1016/j.arth.2019.08.052
- 493 [60] Peng, X., Zhang, H., Xin, P., Bai, G., Ge, Y., Cai, M., . . . Pang, Z. (2022). Synovial  
494 calprotectin for the diagnosis of periprosthetic joint infection: a diagnostic meta-analysis.  
495 *J Orthop Surg Res*, 17(1), 2. doi: 10.1186/s13018-021-02746-2
- 496 [61] Assarsson, E., Lundberg, M., Holmquist, G., Björkesten, J., Thorsen, S. B., Ekman, D., . . .  
497 Fredriksson, S. (2014). Homogenous 96-plex PEA immunoassay exhibiting high  
498 sensitivity, specificity, and excellent scalability. *PLoS One*, 9(4), e95192-e95192. doi:  
499 10.1371/journal.pone.0095192
- 500 [62] Jemal, M. (2000). High-throughput quantitative bioanalysis by LC/MS/MS. *Biomed*  
501 *Chromatogr*, 14(6), 422-429. doi: [https://doi.org/10.1002/1099-](https://doi.org/10.1002/1099-0801(200010)14:6<422::AID-BMC25>3.0.CO;2-I)  
502 [0801\(200010\)14:6<422::AID-BMC25>3.0.CO;2-I](https://doi.org/10.1002/1099-0801(200010)14:6<422::AID-BMC25>3.0.CO;2-I)

503 **Table 1. Proteins differentially abundant in *Staphylococcus aureus* periprosthetic joint**  
 504 **infection (PJI) versus non-infectious arthroplasty failure (NIAF) sonicate fluid samples by**  
 505 **liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis.** Proteins with  
 506 increased and decreased abundance in *S. aureus* PJI compared to NIAF samples are unshaded  
 507 and shaded, respectively. Statistical significance was determined using 2-sample t-test p-values  
 508  $\leq 0.05$  and  $\log_2$ fold-change values  $\geq 2$  or  $\leq -2$ . Data depicted are for NIAF (n=4) and *S. aureus* PJI  
 509 (n=4) sonicate fluid samples.


Protein description	Gene symbol	p-value	$\log_2$ Fold-change
Lactotransferrin	LTF	0.0061	5.198
Lipocalin-2	LCN2	0.0032	5.001
Myeloperoxidase	MPO	0.0084	4.896
Calprotectin (A9 subunit)	S100A9	0.0003	4.531
Cathepsin G	CTSG	0.0177	4.037
Calprotectin (A8 subunit)	S100A8	0.0119	3.951
Neutrophil elastase	ELANE	0.0128	3.780
Eosinophil cationic protein	RNASE3	0.0154	3.629
Endoplasmic reticulum to nucleus signaling 1	ERN1	0.0062	3.169
Matrix metalloproteinase-9	MMP9	0.0151	2.933
Lysozyme C	LYZ	0.0049	2.699
Haptoglobin	HP	0.0169	2.598
Lamin-B1	LMNB1	0.0007	2.492
Glycogen phosphorylase, liver form	PYGL	0.0059	2.471
Leucine-rich alpha-2-glycoprotein	LRG1	0.0067	2.169
Cathepsin D	CTSD	0.0385	-2.007
Fatty acid-binding protein, heart	FABP3	0.0197	-2.031
Fructose-1,6-bisphosphatase 1	FBP1	0.0218	-2.039
Fatty acid-binding protein, epidermal	FABP5	0.0222	-2.063
Collagen alpha-2(I) chain	COL1A2	0.0035	-2.085
Early endosome antigen 1	EEA1	0.0360	-2.111
Heat shock protein beta-1	HSPB1	0.0118	-2.127
Dihydrolipoamide S-succinyltransferase	DLST	0.0256	-2.304
Branched-chain-amino-acid aminotransferase	BCAT1	0.0151	-2.315
Annexin A2	ANXA2	0.0015	-2.363
Serpin B6	SERPINB6	0.0439	-2.384
CD44 antigen	CD44	0.0020	-2.451
Dermcidin	DCD	0.0435	-2.458
Ribonuclease pancreatic	RNASE1	0.0184	-2.541

Proteoglycan 4	PRG4	0.0037	-2.563
Beta-hexosaminidase subunit beta	HEXB	0.0494	-2.662
Osteopontin	SPP1	0.0099	-2.690
IFI30 lysosomal thiol reductase	IFI30	0.0237	-2.798
Cell surface glycoprotein MUC18	MCAM	0.0221	-4.240
Cartilage acidic protein 1	CRTAC1	0.0025	-5.297




510 **Figure 1. Differential analysis of proteins identified in sonicate fluids from periprosthetic**  
511 **joint infection (PJI) and non-infectious arthroplasty failure (NIAF) using liquid**  
512 **chromatography–tandem mass spectrometry analysis.** Volcano plot showing statistically  
513 significant proteins differentially abundant in sonicate fluid from PJI cases. Proteins with  
514 increased and decreased abundance were indicated in red and blue, respectively. The top five  
515 DAPs are labelled. Vertical dashed lines designate  $\log_2$ Fold-change value of  $\pm 2$ -fold and the  
516 horizontal dashed line designates a p-value = 0.05. Statistical significance was determined  
517 using 2-sample t-test with multiple hypothesis correction (p-values  $\leq 0.05$  and  $\log_2$ fold-change  
518 values  $\geq 2$  or  $\leq -2$ ). Data depicted are of NIAF (n=4) and *S. aureus* PJI (n=4) sonicate fluid  
519 samples.





**Figure 2. Differential abundant proteins clearly segregate sonicate fluid samples with *Staphylococcus aureus* periprosthetic joint infection (PJI) from non-infectious arthroplasty failure (NIAF).** (A) Heatmap visualization of protein expression z-scores in NIAF and *S. aureus* PJI samples, with differentially abundant proteins and patient samples clustered. (B) Principal component analysis of NIAF and *S. aureus* PJI samples, with ellipses corresponding with 85% confidence intervals. Statistical significance was determined using 2-sample t-test with multiple hypothesis correction ( $p$ -values  $\leq 0.05$  and  $\log_2$ fold-change values  $\geq 2$  or  $\leq -2$ ). Data depicted are of NIAF ( $n=4$ ) and *S. aureus* PJI ( $n=4$ ) sonicate fluid samples.



520 **Figure 3. Gene ontology analysis of proteins differentially abundant in *S. aureus***  
521 **periprosthetic joint infection (PJI) versus non-infectious arthroplasty failure (NIAF)**  
522 **sonicate fluid samples. (A) Biological processes and (B) Molecular functions enriched using**  
523 **the Gene Ontology 2021 knowledgebase. Gene ontology terms listed with those most**  
524 **statistically significant on top. Data depicted are of NIAF (n=4) and *S. aureus* PJI (n=4)**  
525 **sonicate fluid samples.**